Skip to content

Metabolic Fate of Hallucinogenic NBOMes

Sebastian Leth-Petersen, Charlotte Gabel‐Jensen, Nic Gillings, Szabolzs Lehel, Hanne D. Hansen, Gitte M. Knudsen, Jesper L. Kristensen

Chemical Research in Toxicology December 16, 2015 DOI: 10.1021/acs.chemrestox.5b00450 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational study Peer reviewed
Population Pigs and humans
Intervention 25B-NBOMe
Keywords Hallucinogen Pharmacology
Citations 43
Key findings The primary route of metabolism of 25B-NBOMe is 5'-demethylation, followed by conjugation to glucuronic acid.

Abstract

2,5-Dimethoxy-N-benzylphenethylamines (NBOMes) are very potent 5-HT2AR agonists. Illicit use of these psychedelic compounds has emerged in recent years, and several fatalities have been linked to their recreational use. In its [(11)C]-labeled form, one NBOMe (25B-NBOMe) was recently developed as a PET-ligand for clinical investigations of 5HT2AR ([(11)C]Cimbi-36). Herein, we have identified the phase I and phase II metabolites of 25B-NBOMe in pigs as well as in humans. We find that the primary route of metabolism is 5'-demethylation, followed by conjugation to glucuronic acid. Carbon-11 labeling of 25B-NBOMe in three different positions followed by in vivo evaluation in pigs and humans corroborated these findings.

Citations in the library